CurrentCapital BluecrossPolicy MP 4.046

SPHENOPALATINE GANGLION BLOCK FOR HEADACHE

Defines Capital Blue Cross medical policy MP 4.046 on coverage for sphenopalatine ganglion (SPG) blocks for all headache indications, including migraines, cluster headaches, and postdural puncture headache, and provides coding and background. Applies to certain Capital Blue Cross products with benefit variations.

Policy Summary

PayerCapital Bluecross

PolicySPHENOPALATINE GANGLION BLOCK FOR HEADACHE

Policy CodePolicy MP 4.046

Change TypeClarified (no material change)

Effective DateAug 1, 2025

Next Review Date

Key ActionVerify member's specific Capital Blue Cross product and benefit variations prior to determining coverage; policy applies only to certain programs and products administered by Capital Blue Cross.

POLICY UPDATE CHANGES

Policy statement remained investigational for all headache indications; background, product variation, disclaimer, and coding updated in prior reviews.

Not coveredCoverage stance

3Procedure codes listed

Coverage Summary & Policy Statement

Coverage summary: Policy MP 4.046 (Sphenopalatine ganglion block for headache) is designated investigational / not covered for all headache indications. Effective date: 8/1/2025; last review: 04/07/2025. Headline: Policy MP 4.046 – SPG blocks for headache are investigational and not covered for headache indications.

Medically Necessary / Investigational determination

Policy statement:

Investigational determination: Sphenopalatine ganglion blocks are considered investigational for all headache indications, including but not limited to the treatment of migraines and non-migraine headaches, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Medical Necessity Details

This policy’s medical necessity determination covers sphenopalatine ganglion (SPG) blocks for all headache indications. The policy states that SPG blocks are considered investigational for all headache indications because the evidence is insufficient to demonstrate a net health benefit. The formal, structured determination and decision logic are provided in the policy’s criteria_trees; do not duplicate those criteria here.

Medically Necessary / Investigational determination

Policy statement:

Investigational determination (for utilization review): Sphenopalatine ganglion blocks are considered investigational for all headache indications, including but not limited to the treatment of migraines and non-migraine headaches, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Use this determination to inform utilization review and coverage decisions.

Procedure Codes

Procedure CodesCPT

64400	Injection, anesthetic agent; trigeminal nerve, any division
64505	Percutaneous implantation of neurostimulator electrode array; cranial nerve (e.g., trigeminal branch), open
64999	Unlisted procedure, nervous system

Presence of procedure or billing codes in this policy does not imply coverage. For provider-facing guidance on coding and coverage determinations, follow the official billing rule: verify the member’s specific product and benefits and consult the provider_actions / billing_rule instructions before submitting claims.

Actions for Providers / Billing

Documentation Required

Benefit variation check

Verify member's specific Capital Blue Cross product and benefit variations prior to determining coverage; policy applies only to certain programs and products administered by Capital Blue Cross.

Defines Capital Blue Cross medical policy MP 4.046 on coverage for sphenopalatine ganglion (SPG) blocks for all headache indications, including migraines, cluster headaches, and postdural puncture headache, and provides coding and background. Applies to certain Capital Blue Cross products with benefit variations.

Billing Rule

Codes do not denote coverage

Presence of procedure codes in the coding section does not denote coverage; coverage is determined by member benefit information and medical necessity determination.

64400
64505
64999

Background & Evidence Summary

Background: Sphenopalatine ganglion (SPG) blocks involve intranasal application of topical local anesthetic delivered via commercially available catheters (for example, Tx360®, Allevio®, SpenoCath®) to the mucosa overlying the SPG. They are proposed for acute and preventive treatment of migraines, cluster headaches, and postdural puncture headache (PDPH). Devices are FDA class I and exempt from 510(k) requirements. Available randomized trials and systematic reviews report some short-term pain improvements in select settings but overall the evidence base is limited and insufficient to determine a net health benefit across headache indications.

Study / Evidence	Summary
Chronic migraine RCT	Randomized, double-blind, placebo‑controlled trial of repetitive transnasal SPG blockade (Tx360) with a regimen of 12 treatments over 6 weeks; showed significantly greater short‑term (up to 24 hours) benefit versus placebo but no significant longer‑term effects at 1 and 6 months; trial was underpowered for long‑term outcomes.
Emergency severe headache RCT	Single randomized, double‑blind, placebo‑controlled trial in the emergency setting evaluating a single SPG block for severe acute headache of mixed etiologies; no significant difference at the primary outcome (pain reduction at 15 minutes), but significantly more patients were headache‑free at 24 hours in the active arm.
PDPH systematic review	Meta‑analysis of 9 RCTs (N=381) comparing SPG blocks to controls; SPG blocks significantly improved pain at 30 minutes, 1 hour, and 4 hours but not at later time points (2, 6, 8, 12, or 24 hours); studies varied in anesthetic concentrations and had small sample sizes and multiple design limitations.
Cluster headache evidence	Evidence consists of case series (including small endoscopic approaches different from current U.S. devices) reporting 40%–50% of patients experienced complete symptom relief for variable durations and about 20% had treatment‑related complications; findings are limited and not clearly generalizable to current intranasal devices.

Definitions:

- Chronic migraine: attacks on at least 15 days per month for more than 3 months, with features of migraine on at least 8 days per month.

- Post dural puncture headache (PDPH): a bilateral frontal or occipital headache that worsens with sitting or standing and is relieved in the supine position, occurring after dural puncture or CSF leak.

Revision History

2020-06-17consensus_review

Consensus review: Policy statement unchanged. Product variation, background, benefit variation, disclaimer, and coding updated; references reviewed.

2021-04-20consensus_review

Consensus review: Policy statement unchanged. Background updated to include addition of postdural puncture headache; references updated.

2022-02-22consensus_review

Consensus review: No change in policy statement. Product variation updated and revised FEP language added; background amended; references added.

2023-06-02consensus_review

Consensus review: No change to policy statement. Title changed to Sphenopalatine Ganglion Block for Headache; background and references updated.

2024-06-03consensus_review

Consensus review: No change to policy statement. Background and rationale updated; reference added.

2025-04-07consensus_reviewLatest

Consensus review: No change to policy statement. Background, product variation, and disclaimer updated. Policy statement remained investigational for all headache indications; background, product variation, disclaimer, and coding updated in prior reviews. is_material: false